Emerging in the field of excess body fat treatment, retatrutide represents a distinct strategy. Unlike many existing medications, retatrutide works as a twin agonist, concurrently affecting both GLP peptide-1 (GLP-1) and glucose-sensitive insulinotropic hormone (GIP) binding sites. This concurrent activation promotes several beneficial effects, inc